Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: Results from the GEICAM 2009-03 ConvertHER study

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 507-515

  De Dueñas, Eduardo Martínez ^a   Hernández, Ana Lluch ^b   Zotano, Ángel Guerrero ^c   Carrión, Ramón María Pérez ^d   López Muñiz, José Ignacio Chacón ^e   Novoa, Silvia Antolín ^f   Rodríguez, Ángela López ^a   Fidalgo, José Alejandro Pérez ^b   Lozano, Jaime Ferrer ^b   Gasión, Octavio Burgués ^b   Carrascal, Eva Carrasco ^g   Capilla, Andrés Hernando ^g   López Barajas, Isabel Blancas ^h   Mateu, Montserrat Muñoz ⁱ   De Ceballos Reyna, María Helena López ^j   Ferrando, Amparo Oltra ^k   Jañez, Noelia Martínez ^l   Ballerini, Vicente Carañana ^m   Torres, Antonio Antón ⁿ   Catalán, Gustavo ^o   Sáenz, José Ángel García ^p   Menjón, Salomón ^q   González Angulo, Ana María ^r   more..

^a HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^d HOSPITAL QUIRÓN   (Spain)

^e HOSPITAL VIRGEN DE LA SALUD   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g GEICAM Grupo Español de Investigación en Cáncer de Mama   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^k HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^l HOSPITAL RAMÓN Y CAJAL   (Spain)

^m HOSPITAL ARNAU DE VILANOVA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^o HOSPITAL SON LLÀTZER   (Spain)

^p HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^q HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^r UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

Breast neoplasm; Conversion; HER2; Hormone receptors; Tumor markers

Indexed keywords

ADULT; AGED; BIOPSY; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894027548     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2825-2     Document Type: Article

References (15)

1. Edgerton SM, Moore D 2nd, Merkel D, Thor AD (2003) erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 11:214-221
2. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27:3185-3191. doi: 10.1200/JCO.2008.18.5934
3. Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y (2011) Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 28:57-63. doi: 10.1007/s12032-010- 9418-2
4. Tolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM (2011) Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res 13:R51. doi: 10.1186/bcr2882
5. Arslan C, Sari E, Aksoy S, Altundag K (2011) Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 15:21-30. doi: 10.1517/14656566. 2011.537260
6. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168
7. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795. doi: 10.1200/JCO.2009.25. 6529
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. doi: 10.1200/JCO.2006.09.2775
9. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
10. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592. doi: 10.1200/JCO.2010.33. 5232
11. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12:R92. doi: 10.1186/bcr2771
12. Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM (2012) Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38:708-714. doi: 10.1016/j.ctrv.2011.11.006
13. Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31. doi: 10.1186/bcr1676
14. Amir E, Clemons M (2009) Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 10:933-935. doi: 10.1016/S1470-2045(09)70295-5
15. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ (2009) Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20:1499-1504. doi: 10.1093/annonc/mdp028